Bone and subcutaneous adipose tissue pharmacokinetics of vancomycin in total knee replacement patients

Mats Bue1,2, Mikkel Tøttrup2,3,4, Pelle Hanberg1,2

  • 1a Department of Orthopaedic Surgery , Horsens Regional Hospital , Horsens.

Acta Orthopaedica
|September 16, 2017
PubMed

Insights

Vancomycin penetration into bone and soft tissue is impaired after total knee replacement. Standard prophylactic doses may not achieve adequate concentrations for preventing orthopedic infections like MRSA.

Area of Science:

  • Orthopedic Surgery
  • Infectious Diseases
  • Pharmacokinetics

Background:

  • Increasing incidence of orthopedic methicillin-resistant Staphylococcus aureus (MRSA) infections.
  • Growing importance of vancomycin in perioperative antimicrobial prophylaxis.
  • Limited studies on vancomycin bone and soft tissue concentrations.

Purpose of the Study:

  • To assess vancomycin concentrations in plasma, subcutaneous adipose tissue (SCT), and bone.
  • To evaluate vancomycin penetration using microdialysis in patients undergoing total knee replacement.
  • To determine if standard prophylactic vancomycin doses achieve therapeutic levels in orthopedic tissues.

Main Methods:

  • 10 male patients undergoing primary total knee replacement received 1000 mg vancomycin intravenously.
  • Microdialysis used for sampling vancomycin concentrations in plasma, SCT, cancellous, and cortical bone.
  • Measurements taken over 8 hours post-administration.

Main Results:

  • Vancomycin penetration into bone and SCT was significantly impaired and delayed.
  • Time to reach a minimal inhibitory concentration (MIC) of 2 mg/L was prolonged in tissues compared to plasma.
  • Therapeutic concentrations (MIC of 4 mg/L) were not achieved in cortical bone.

Conclusions:

  • Postoperative vancomycin penetration to bone and SCT is suboptimal in total knee replacement patients.
  • Standard prophylactic vancomycin dosing may be insufficient for effective perioperative prophylaxis.
  • Further research needed to optimize vancomycin dosing strategies for orthopedic surgery.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
312
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
226
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
4.2K
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
274
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
287
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
249